Bristol’s Proposed ImClone Acquisition May Beckon Potential Suitors

If Bristol-Myers Squibb wins its bid for the remaining 83 percent of stock in Erbitux partner ImClone that it does not already own, the evolving biopharma - which itself has been the subject of takeover rumors - could become a more attractive target for potential suitors